Effect of PPARγ agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits

Yaoxue Xuebao

Volumn 40, Issue 11, 2005, Pages 1051-1053

  Wang, Zhao Hui ^a   Luo, Feng ^a   Liu, Xiao Mei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Atherosclerosis; Cholesterol; Peroxisome proliferator activated receptor ; Rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL; FIBRINOLYTIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANIMAL; AORTA; ARTICLE; ATHEROSCLEROSIS; BLOOD; CHOLESTEROL INTAKE; DRUG POTENTIATION; HYPERCHOLESTEROLEMIA; INTIMA; MALE; PATHOLOGY; RABBIT; RANDOMIZATION;

ANIMALS; AORTA; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; FIBRINOLYTIC AGENTS; HYPERCHOLESTEROLEMIA; MALE; PPAR GAMMA; RABBITS; RANDOM ALLOCATION; THIAZOLIDINEDIONES; TUNICA INTIMA;

EID: 29744450335     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Wang ZH, Gan Q, Han SJ, et al. The regulations of peroxisome proliferator-activated receptor-γ on apoptotic related genes p53 and bcl-2 in cultured vascular smooth muscle cells [J]. Chin J Pathophysiol, 2004, 20(4):590-594.
2. Zhang JT. Modern Pharmacology Experiment Methods [M]. Beijing: Peking Union Medical College and Beijing Medical University Press, 1998. 1267.
3. Raji A, Seely EW, Bekins SA, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients [J]. Diabetes Care, 2003, 26(1):172-178.
4. Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels [J]. Clin Ther, 2003, 25(Suppl B):B64-80.
5. Levi Z, Shaish A, Yacov N, et al. Rosiglitazone (PPARγ-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model [J]. Diabetes Obes Metab, 2003, 5(1):45-50.
6. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice [J]. J Clin Invest, 2000, 106(4):523-531.
7. Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL [J]. Arterioscler Thromb Vasc Biol, 2001, 21(3):372-377.
8. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis [J]. Arterioscler Thromb Vasc Biol, 2002, 22(5):717-726.
9. Corti R, Osende JI, Fallon JT, et al. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging [J]. J Am Coll Cardiol, 2004, 43(3):464-473.
10. Iida KT, Kawakami Y, Suzuki H, et al. PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages [J]. FEBS Lett, 2002, 520(1-3):177-181.